Otsuka America Pharmaceutical, Inc. (Otsuka)

Oncology Corporate Profile

HQ Location

2440 Research Blvd
Rockville, MD 20850

Company Description

Otsuka America Pharmaceutical, Inc. (OAPI) is part of the Otsuka Group (Otsuka). OAPI was established in the U.S. in 1989 and is responsible for all pharmaceutical and medical device commercial activities in North America.


Brand Generic Indication
Busuflex®busulfanBusuflex® (busulfan) Injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia.
Sprycel®dasatinibSprycel® is a kinase inhibitor indicated for:

• treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib.

• treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
AT13387HSP90 inhibitor2nd line metastatic Gastrointestinal Stromal Tumors (GIST)II
SGI-110DNA methyltransferase inhibitorAcute Myelogenous Leukemia (AML)II
AT7519CDK inhibitorChronic Lymphocytic Leukemia (CLL)IINovartis
AT7519CDK inhibitorMantel Cell Lymphoma (MCL)IINovartis
AT9283Aurora/JAK2 inhibitorMultiple MyelomaII
AT7519 (+ bortezomib)CDK inhibitorMultiple MyelomaIINovartis
SGI-110DNA methyltransferase inhibitorMyelodysplastic Syndrome (MDS)II
AT13387HSP90 inhibitorNon Small Cell Lung Cancer (NSCLC)II
AT13387HSP90 inhibitor2nd line metastatic castrate-resistant prostate cancer (CRPC)I
OPB 51602stat3 inhibitorVarious cancer typesI
AT7519CDK inhibitorVarious cancer typesINovartis
LEE011CDK4 inhibitorVarious cancer typesINovartis
AZD5363PKB/Akt inhibitorVarious cancer typesIAstraZeneca
AT9283Aurora/JAK2 inhibitorVarious cancer typesI

View additional information on product candidates here »


Recent News Headlines

There are no news items to display